

# Peter A Riedell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8482926/publications.pdf>

Version: 2024-02-01

63  
papers

823  
citations

623734

14  
h-index

526287

27  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	1.4	66
2	Primary Analysis of Zuma-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S1.	1.2	0
3	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 669-676.	1.2	36
4	Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early-Phase Cellular Therapy Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 105-107.	1.2	1
5	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. <i>Leukemia and Lymphoma</i> , 2021, 62, 1497-1501.	1.3	1
6	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	1.0	10
7	Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study. <i>Journal of Clinical Oncology</i> , 2021, 39, e19537-e19537.	1.6	6
8	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3454-3459.	1.4	4
9	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
10	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	1.2	6
11	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	2.5	5
12	Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S245.	0.4	0
13	IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S403-S404.	0.4	0
14	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 739-739.	1.4	12
15	Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). <i>Blood</i> , 2021, 138, 3847-3847.	1.4	7
16	Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium. <i>Blood</i> , 2021, 138, 2843-2843.	1.4	1
17	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	1.4	8
18	A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 2512-2512.	1.4	3

#	ARTICLE	IF	CITATIONS
19	First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SW1019). <i>Blood</i> , 2021, 138, 2822-2822.	1.4	1
20	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aB NHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 429-429.	1.4	9
21	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	1.4	16
22	Antigen multimers: Specific, sensitive, precise, and multifunctional high-avidity CAR-staining reagents. <i>Matter</i> , 2021, 4, 3917-3940.	10.0	4
23	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 799-807.	1.3	10
24	Advances in CAR T-Cell Therapy for Aggressive B-NHL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S94-S97.	0.4	1
25	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	3.5	16
26	Recommendations from a Geriatric Assessment (GA) Guided Multidisciplinary Clinic (MDC) in Older Patients for Autologous Hematopoietic Cell Transplant (autoHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S23.	2.0	0
27	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	2.4	11
28	A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S41-S42.	2.0	27
29	Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1025-1027.	2.0	20
30	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
31	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090289.	2.5	13
32	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 4-6.	1.4	7
33	First Reported Use of Artesunate Adjunctive Therapy for Severe BK Polyoma Virus Hemorrhagic Cystitis (BKPyV-HC). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S349-S350.	2.0	0
34	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). <i>Blood</i> , 2020, 136, 39-40.	1.4	0
35	Factors Influencing Prescribing Patterns and Patient Management Among US Centers Offering Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for B-NHL. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S174.	2.0	0
36	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.	5.2	62

#	ARTICLE	IF	CITATIONS
37	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1956-1956.	1.4	2
38	A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucl in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). <i>Blood</i> , 2019, 134, 4093-4093.	1.4	8
39	A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucl and Tisagenlecleucl for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 1599-1599.	1.4	45
40	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucl (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 503-503.	1.4	24
41	Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucl and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5325-5325.	1.4	13
42	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 1550-1550.	1.4	1
43	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. <i>Blood</i> , 2019, 134, 3324-3324.	1.4	0
44	Resistance to Axicabtagene Ciloleucl Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 5238-5238.	1.4	0
45	Diagnostic Evaluation in Primary CNS Lymphoma. <i>Neurologist</i> , 2018, 23, 53-54.	0.7	6
46	Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 91-97.	0.4	4
47	Outcomes after Alemtuzumab-Based Conditioning Therapy and Allogeneic Transplantation for Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S339.	2.0	0
48	Axicabtagene Ciloleucl (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S293-S294.	0.4	0
49	Double hit and double expressors in lymphoma: Definition and treatment. <i>Cancer</i> , 2018, 124, 4622-4632.	4.1	121
50	TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. <i>Blood</i> , 2018, 132, 2984-2984.	1.4	3
51	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018, 132, 2929-2929.	1.4	0
52	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , 2017, 130, 816-816.	1.4	7
53	Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. <i>American Journal of Hematology</i> , 2016, 91, 1002-1007.	4.1	39
54	Factors Associated with Progression-Free Survival in Mantle Cell Lymphoma Patients Treated with Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S229-S230.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 313-319.	1.3	5
56	The Role of HIV in Race-Based Differences in Diffuse Large B-Cell Lymphoma (DLBCL) Treatment and Outcomes. <i>Blood</i> , 2016, 128, 1189-1189.	1.4	0
57	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.	1.0	47
58	Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. <i>British Journal of Haematology</i> , 2014, 167, 699-702.	2.5	15
59	A drug safety evaluation of rituximab and risk of hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 977-987.	2.4	16
60	Racial Differences in Treatment Dose Intensity Among Patients with Diffuse Large B-Cell Lymphoma: Analysis of the Veterans Health Administration (VHA) National Database. <i>Blood</i> , 2014, 124, 554-554.	1.4	0
61	Venous Thromboembolism In Patients With Non-Hodgkin Lymphoma: Analysis Of The Veterans Health Administration (VHA) National Database. <i>Blood</i> , 2013, 122, 1701-1701.	1.4	0
62	Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database. <i>Blood</i> , 2012, 120, 968-968.	1.4	1
63	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. <i>Blood Advances</i> , 0, , .	5.2	3